1073319-23-9

Basic information

• Product Name: methyl 3-[2-(2-bromo-5-fluorophenoxy)ethoxy]isoxazole-5-carboxylate
• Synonyms: methyl 3-[2-(2-bromo-5-fluorophenoxy)ethoxy]isoxazole-5-carboxylate
• CAS NO: 1073319-23-9
• Molecular Weight: 360.136
• Mol File: 1073319-23-9.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: methyl 3-[2-(2-bromo-5-fluorophenoxy)ethoxy]isoxazole-5-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3-[2-(2-bromo-5-fluorophenoxy)ethoxy]isoxazole-5-carboxylate(1073319-23-9)
• EPA Substance Registry System: methyl 3-[2-(2-bromo-5-fluorophenoxy)ethoxy]isoxazole-5-carboxylate(1073319-23-9)

Safety Data

• Hazardous Substances Data: 1073319-23-9(Hazardous Substances Data)

Upstream product

• 1073318-98-5 2-(2-bromo-5-fluorophenoxy)ethanol 
• 10068-07-2 methyl 3-hydroxy-5-isoxazolecarboxylate 
• 147460-41-1 2-bromo-5-fluorophenol 

Downstream Products

• 1073318-19-0 (5-{3-[2-(2-bromo-5-fluorophenoxy)ethoxy]isoxazol-5-yl}-1H-tetrazol-1-yl)acetic acid 
• 1073319-28-4 ethyl (5-{3-[2-(2-bromo-5-fluorophenoxy)ethoxy]isoxazol-5-yl}-1H-tetrazol-1-yl)acetate 
• 1073319-27-3 ethyl (5-{3-[2-(2-bromo-5-fluorophenoxy)ethoxy]isoxazol-5-yl}-1H-tetrazol-1-yl)acetate 
• 1073318-18-9 (5-{3-[2-(2-bromo-5-fluorophenoxy)ethoxy]isoxazol-5-yl}-2H-tetrazol-2-yl)acetic acid 
• 1073319-26-2 5-{3-[2-(2-bromo-5-fluorophenoxy)ethoxy]isoxazol-5-yl}-1H-tetrazole 
• 1073319-24-0 3-[2-(2-bromo-5-fluorophenoxy)ethoxy]isoxazole-5-carboxamide 

Relevant articles and documents

Discovery of potent and liver-selective stearoyl-CoA desaturase (SCD) inhibitors in an acyclic linker series

Elevated levels of stearoyl-CoA desaturase (SCD) activity have been implicated in metabolic disorders such as obesity and type II diabetes. To circumvent skin and eye adverse events observed in rodents with systemically-distributed inhibitors, our research efforts have been focused on the search for new liver-targeting compounds. This work has led to the discovery of novel, potent and liver-selective acyclic linker SCD inhibitors. These compounds possess suitable cellular activity and pharmacokinetic properties to inhibit liver SCD activity in a mouse pharmacodynamic model.